Reports Q4 revenue $42.5B, consensus $42.09B. “We are pleased to have delivered another year of strong performance in 2023, enabled by our relentless focus on customer experience and affordability, and continued investments in growth and innovation. The balance and resilience of our business coupled with the focused execution of our enterprise strategy supports our confidence in our outlook for 2024, as we continue to optimize the foundation, and scale our flywheel for sustained growth of the enterprise over the long term.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ELV:
- Is ELV a Buy, Before Earnings?
- Early notable gainers among liquid option names on January 17th
- PEAK ROCK CAPITAL AFFILIATE SELLS PARAGON HEALTHCARE, INC. TO ELEVANCE HEALTH
- Peak Rock Capital affiliate to sell Paragon Healthcare to Elevance Health
- Elevance Health to buy Paragon Infusion for ‘well north’ of $1B, Axios says
